In summary, baricitinib 4 mg can significantly increase ALT, creatinine, LDL-C levels, and the risk of infections; therefore, dose reduction is considered for patients with hepatic and renal insufficiency, hyperlipidemia, and mild to moderate severity infections. This evidence concerns the gene GPT and hyperlipidemia.